Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (11528)	2/8/2018 2:32:36 PM
From: Miljenko Zuanic	Respond to of 12215

MDGL CC: Very confusing and/or not-helping CC, rise more qs than answer them. Two main concern in regards the MGL-3196 is; 1. Optimal dosing (how to predict when you have selective and specific liver targeting agent), and 2. Magnitude of the effects on lipids and triglycerides, when you do not adjust for placebo (positive drift)??? In all, maybe VK2809 is better agent than 3196, at least for HeFH related conditions (in P1b/2a show better results on factor/marker measurements, more predictable dosing...max 20 mg, titration from 10 mg)???